FDA Approves Extended Dosing Intervals for EYLEA HD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy REGN?
Source: NASDAQ.COM
- FDA Approval of New Dosing Regimen: The FDA has approved EYLEA HD (Aflibercept) to extend dosing intervals up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), based on 96-week data from the PULSAR and PHOTON trials, demonstrating sustained visual and anatomical improvements, thereby enhancing treatment flexibility and patient adherence.
- Significant Clinical Trial Results: Among wAMD patients, 71% and 47% achieved the last assigned dosing intervals of 16 and 20 weeks, respectively, while 72% and 44% of DME patients reached similar targets, indicating EYLEA HD's effectiveness in extending dosing intervals, which reduces treatment burden for patients.
- Huge Market Potential: The new dosing regimen allows patients to be treated as infrequently as 2 to 3 times a year, making EYLEA HD the only injectable anti-VEGF therapy with such long dosing intervals, which is expected to attract more patients and further solidify Regeneron's leadership in the ophthalmic treatment market.
- Positive Future Outlook: The FDA is also set to review the EYLEA HD prefilled syringe in April 2026, and if approved, it will further expand market coverage; Regeneron anticipates achieving long-term growth through this innovative product line to meet the increasing patient demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 767.850
Low
637.00
Averages
808.50
High
1057
Current: 767.850
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dupixent Approved in EU for Children with CSU
- Expanded Indication for Children: Dupixent (dupilumab) has received EU approval for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of its indications and providing a new treatment option for this vulnerable population, which is expected to greatly improve their quality of life.
- Clinical Trial Validation: The approval is based on data from the LIBERTY-CUPID clinical trial program, demonstrating that Dupixent significantly reduced urticaria activity in adults, with safety and efficacy in children being consistent with adult profiles, further solidifying its position as a preferred treatment.
- Significant Market Potential: As one of the most widely used innovative antibody medicines globally, Dupixent's approval in the pediatric population is expected to drive sales growth, particularly in addressing chronic diseases driven by type 2 inflammation, meeting the urgent market demand for effective treatments.
- Raising Treatment Standards: The approval of Dupixent not only provides new treatment options for children but may also establish a new standard of care for CSU, reflecting the pharmaceutical industry's commitment to addressing unmet medical needs and enhancing market recognition of the drug.
See More
Dupixent Approved in EU for Treating Children with CSU
- Pediatric Indication Expansion: Dupixent (dupilumab) has been approved in the EU as the first targeted therapy for chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking a significant breakthrough for the company in the pediatric market and expected to enhance market share.
- Clinical Study Support: The approval is based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's significant reduction in urticaria activity in adults, with efficacy data in children indicating its potential to improve symptoms, further solidifying Dupixent's market position.
- Improved Treatment Options: Dupixent offers a new treatment option for children whose symptoms are inadequately controlled by antihistamines, addressing the suffering many children face during critical growth years, which is expected to enhance their quality of life and reduce healthcare burdens.
- Global Market Outlook: With approvals in over 60 countries, the expansion of pediatric indications for Dupixent is anticipated to drive sales growth, further solidifying Sanofi and Regeneron's leadership in the biopharmaceutical sector.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Approval Expansion: The European Commission has approved Dupixent (Dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of the drug's indications to address the urgent needs of children unresponsive to antihistamines.
- Clinical Trial Support: This approval is based on data from the LIBERTY-CUPID clinical trial program, which demonstrated that Dupixent significantly reduced urticaria activity in adults, further validating its efficacy and safety in the pediatric population.
- Global Market Performance: Dupixent has received regulatory approvals in over 60 countries, with Sanofi reporting global net sales of $17.8 billion for 2025, a significant increase from the previous year, indicating strong market demand and potential for the drug.
- Market Reaction: Despite the positive approval news, Sanofi's stock fell 0.68% in Friday's trading and continued to decline by 0.97% in pre-market trading, reflecting a cautious market sentiment towards the biopharmaceutical sector.
See More
Telix and Regeneron Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration Model: Telix and Regeneron have established a 50/50 cost and profit-sharing agreement to co-develop next-generation radiopharmaceuticals, combining Telix's expertise in radiopharmaceutical development with Regeneron's antibody discovery platform, which is expected to significantly enhance both companies' market competitiveness in precision oncology.
- Initial Funding Injection: Telix will receive an upfront payment of $40 million for four initial programs, with the potential for additional co-funding on a per-program basis, leading to a total of up to $2.1 billion in development and commercial milestone payments, thereby strengthening Telix's financial stability and R&D capabilities.
- Market Potential: The collaboration will target multiple solid tumor indications using antibodies generated from Regeneron's VelocImmune® mice, which is expected to provide new treatment options for patients, particularly in high unmet need areas like lung cancer, potentially altering existing treatment standards.
- Diagnostic Asset Development: Telix will lead the commercialization of diagnostic assets, with Regeneron receiving a set percentage of profits, a strategy that not only deepens the collaboration but may also enhance patient treatment outcomes and satisfaction through precision diagnostics.
See More
Regeneron and Telix Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration Model: Regeneron and Telix have established a 50/50 cost and profit-sharing agreement to co-develop next-generation radiopharmaceuticals, combining Regeneron's expertise in antibody discovery and oncology with Telix's capabilities in radiopharmaceutical development, which is expected to significantly enhance both companies' competitive positions in the precision oncology market.
- Initial Investment: Telix will receive an upfront payment of $40 million for the development of four initial programs, providing strong financial support for Telix while also offering Regeneron an entry point into the radiopharmaceutical market, which is anticipated to drive future revenue growth.
- Potential Earnings: Under the collaboration, Telix could earn up to $2.1 billion in development and commercial milestone payments, along with low double-digit royalties on future sales, which will greatly enhance Telix's long-term financial performance and strengthen its position in the biopharmaceutical industry.
- Market Outlook: The parties plan to jointly develop diagnostic assets, with Telix leading commercialization and Regeneron sharing profits, a strategy that not only enhances the precision of patient selection and treatment response assessment but also opens new growth avenues for both companies in the rapidly evolving radiopharmaceutical market.
See More
European Commission Approves DPREMIUM
- Drug Approval: Regeneron and Sanofi announced that the European Commission has approved their new drug DPREMIUM, which will support their competitiveness in the European market and is expected to drive sales growth.
- Market Potential: The approval of DPREMIUM means the companies can meet the increasing patient demand in Europe, thereby enhancing their market share in the biopharmaceutical sector, particularly in treating specific diseases.
- Strategic Partnership: This approval further solidifies the collaboration between Regeneron and Sanofi, as both companies will jointly promote DPREMIUM, which is expected to accelerate the product's market launch.
- Future Outlook: With the launch of DPREMIUM, Regeneron and Sanofi anticipate a new revenue stream, strengthening their position in the global pharmaceutical market, especially in the highly competitive biopharmaceutical industry.
See More
Dupixent Approved in EU for Children with CSU
- Expanded Indication for Children: Dupixent (dupilumab) has received EU approval for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of its indications and providing a new treatment option for this vulnerable population, which is expected to greatly improve their quality of life.
- Clinical Trial Validation: The approval is based on data from the LIBERTY-CUPID clinical trial program, demonstrating that Dupixent significantly reduced urticaria activity in adults, with safety and efficacy in children being consistent with adult profiles, further solidifying its position as a preferred treatment.
- Significant Market Potential: As one of the most widely used innovative antibody medicines globally, Dupixent's approval in the pediatric population is expected to drive sales growth, particularly in addressing chronic diseases driven by type 2 inflammation, meeting the urgent market demand for effective treatments.
- Raising Treatment Standards: The approval of Dupixent not only provides new treatment options for children but may also establish a new standard of care for CSU, reflecting the pharmaceutical industry's commitment to addressing unmet medical needs and enhancing market recognition of the drug.
See More
Dupixent Approved in EU for Treating Children with CSU
- Pediatric Indication Expansion: Dupixent (dupilumab) has been approved in the EU as the first targeted therapy for chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking a significant breakthrough for the company in the pediatric market and expected to enhance market share.
- Clinical Study Support: The approval is based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's significant reduction in urticaria activity in adults, with efficacy data in children indicating its potential to improve symptoms, further solidifying Dupixent's market position.
- Improved Treatment Options: Dupixent offers a new treatment option for children whose symptoms are inadequately controlled by antihistamines, addressing the suffering many children face during critical growth years, which is expected to enhance their quality of life and reduce healthcare burdens.
- Global Market Outlook: With approvals in over 60 countries, the expansion of pediatric indications for Dupixent is anticipated to drive sales growth, further solidifying Sanofi and Regeneron's leadership in the biopharmaceutical sector.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Approval Expansion: The European Commission has approved Dupixent (Dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of the drug's indications to address the urgent needs of children unresponsive to antihistamines.
- Clinical Trial Support: This approval is based on data from the LIBERTY-CUPID clinical trial program, which demonstrated that Dupixent significantly reduced urticaria activity in adults, further validating its efficacy and safety in the pediatric population.
- Global Market Performance: Dupixent has received regulatory approvals in over 60 countries, with Sanofi reporting global net sales of $17.8 billion for 2025, a significant increase from the previous year, indicating strong market demand and potential for the drug.
- Market Reaction: Despite the positive approval news, Sanofi's stock fell 0.68% in Friday's trading and continued to decline by 0.97% in pre-market trading, reflecting a cautious market sentiment towards the biopharmaceutical sector.
See More
Telix and Regeneron Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration Model: Telix and Regeneron have established a 50/50 cost and profit-sharing agreement to co-develop next-generation radiopharmaceuticals, combining Telix's expertise in radiopharmaceutical development with Regeneron's antibody discovery platform, which is expected to significantly enhance both companies' market competitiveness in precision oncology.
- Initial Funding Injection: Telix will receive an upfront payment of $40 million for four initial programs, with the potential for additional co-funding on a per-program basis, leading to a total of up to $2.1 billion in development and commercial milestone payments, thereby strengthening Telix's financial stability and R&D capabilities.
- Market Potential: The collaboration will target multiple solid tumor indications using antibodies generated from Regeneron's VelocImmune® mice, which is expected to provide new treatment options for patients, particularly in high unmet need areas like lung cancer, potentially altering existing treatment standards.
- Diagnostic Asset Development: Telix will lead the commercialization of diagnostic assets, with Regeneron receiving a set percentage of profits, a strategy that not only deepens the collaboration but may also enhance patient treatment outcomes and satisfaction through precision diagnostics.
See More
Regeneron and Telix Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration Model: Regeneron and Telix have established a 50/50 cost and profit-sharing agreement to co-develop next-generation radiopharmaceuticals, combining Regeneron's expertise in antibody discovery and oncology with Telix's capabilities in radiopharmaceutical development, which is expected to significantly enhance both companies' competitive positions in the precision oncology market.
- Initial Investment: Telix will receive an upfront payment of $40 million for the development of four initial programs, providing strong financial support for Telix while also offering Regeneron an entry point into the radiopharmaceutical market, which is anticipated to drive future revenue growth.
- Potential Earnings: Under the collaboration, Telix could earn up to $2.1 billion in development and commercial milestone payments, along with low double-digit royalties on future sales, which will greatly enhance Telix's long-term financial performance and strengthen its position in the biopharmaceutical industry.
- Market Outlook: The parties plan to jointly develop diagnostic assets, with Telix leading commercialization and Regeneron sharing profits, a strategy that not only enhances the precision of patient selection and treatment response assessment but also opens new growth avenues for both companies in the rapidly evolving radiopharmaceutical market.
See More
European Commission Approves DPREMIUM
- Drug Approval: Regeneron and Sanofi announced that the European Commission has approved their new drug DPREMIUM, which will support their competitiveness in the European market and is expected to drive sales growth.
- Market Potential: The approval of DPREMIUM means the companies can meet the increasing patient demand in Europe, thereby enhancing their market share in the biopharmaceutical sector, particularly in treating specific diseases.
- Strategic Partnership: This approval further solidifies the collaboration between Regeneron and Sanofi, as both companies will jointly promote DPREMIUM, which is expected to accelerate the product's market launch.
- Future Outlook: With the launch of DPREMIUM, Regeneron and Sanofi anticipate a new revenue stream, strengthening their position in the global pharmaceutical market, especially in the highly competitive biopharmaceutical industry.
See More
